NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm announces that it is investigating potential civil securities claims against AngioDynamics, Inc. (NASDAQ: ANGO). AngioDynamics is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. The investigation relates to AngioDynamics’ announcement of its financial results for the third quarter of 2015 on April 9, 2015. AngioDynamics reported a quarterly loss of $4.3 million and advised investors of a downgrade in its full year outlook by nearly 4%. On this news, AngioDynamics’ stock declined by as much as 8% on heavy volume.
If you purchased AngioDynamics shares prior to April 9, 2015, please visit the firm’s website at http://www.rosenlegal.com/cases-620.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.